Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LPCAT1 Double Nickase Plasmid (h): sc-413287-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LPCAT1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LPCAT1 Double Nickase Plasmid (h) and LPCAT1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LPCAT1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LPCAT1 Antibody (F-9): sc-518182
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LPCAT1 Double Nickase Plasmid (h) | sc-413287-NIC | 20 µg | $410.00 |
LPCAT1 (lysophosphatidylcholine acyltransferase 1) is an ER-associated acyltransferase that catalyzes the reacylation of lysophosphatidylcholine to phosphatidylcholine, supporting membrane biogenesis and phospholipid remodeling within the Lands’ cycle. By shaping phosphatidylcholine species composition, LPCAT1 influences membrane curvature, vesicle trafficking, and lipid-dependent signaling, and it contributes to surfactant phospholipid production in specialized epithelial contexts. Altered LPCAT1 expression or activity has been linked to dysregulated lipid metabolism programs and has been investigated in models of tumor progression and inflammatory microenvironments where membrane synthesis and remodeling are heightened. As a node in glycerophospholipid metabolism, LPCAT1 is frequently studied for its impact on cellular stress responses, proliferation, and metabolic adaptation.
LPCAT1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LPCAT1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LPCAT1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LPCAT1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LPCAT1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.